King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale
This article was originally published in RPM Report
Executive Summary
Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?
You may also be interested in...
Abuse-Deterrent Opioids: Where Are They Now?
The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.
Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another
Pfizer got its first abuse-deterrent claim for its pain therapy Embeda. But it has also ended an agreement to develop another potential abuse-deterrent pain drug.
The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence
Pfizer’s acquisition of King gave the company a chance to play in a new kind of market: abuse deterrent opioid pain relief formulations. Two years later, Pfizer is moving in the other direction, even as FDA’s actions validate the notion that there is an opportunity—and that the scale of Big Pharma can play a critical role.